News and Announcements

Biogen to buy Apellis Pharmaceuticals in $5.6bn deal

By Michele Maatouk

Date: Tuesday 31 Mar 2026

(Sharecast News) - Shares in Apellis Pharmaceuticals rocketed on Tuesday after it agreed to be bought by Biogen in a $5.6bn deal.
Under the terms of the acquisition, Biogen will pay $41 per share in cash.

Apellis stockholders will also receive a non-transferable CVR for each Apellis share held, entitling...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page